Navigation Links
Indonesia's Pharmaceutical companies Get Boost in Competitive Advantage from Launch of Newport Horizon Premium and IDRAC Solutions by Thomson Reuters
Date:8/25/2008

Industry Leader in Generic Market Information Offers Single Authoritative Source of API Sourcing and Global Regulatory Intelligence to Indonesia's

Generics and API Manufacturers

JAKARTA, Indonesia, Aug. 26 /Xinhua-PRNewswire/ -- Indonesia's generics and API (Active Pharmaceutical Ingredient) manufacturers get boost in competitive advantage from launch of two solutions in the market by the Scientific business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals. Newport Horizon Premium(TM) is designed specifically for professionals working in product selection, business development, competitive intelligence and API (Active Pharmaceutical Ingredient) sourcing. IDRAC(R) is a single comprehensive source of global regulatory intelligence. Their use by generic and OTC (Over the Counter) pharmaceutical companies and API manufacturers in Indonesia will enable them to develop products more quickly, keep up with changing global regulatory requirements and speed product registration and commercialisation, thereby expanding their business footprint in Asia and beyond.

The two solutions can help provide a competitive boost to Indonesia's pharmaceutical industry which is forecast to reach US$3.75bn in value by 2012 according to Business Monitor International in April 2008.

Said Mr. Wong Woei Fuh, Commercial Director Asia Pacific, Scientific business of Thomson Reuters, "To stay competitive in the generics market, pharmaceutical companies and API manufacturers in Indonesia have a critical need for authoritative market information as well as time and money-saving API sourcing solutions. Customers will benefit from our one-stop global resource of intelligence which will help them improve productivity, accelerate time to market and gain that competitive edge to expand their footprint globally, part of the government's drive to promote the local pharmaceuticals industry. As the industry authority on the global generics market, we believe Newport Horizon Premium and IDRAC are well-placed to help Indonesia's pharmaceutical industry expand its capability."

Newport Horizon Premium (NHP) combines sales, consumption, launch, patent, patent challenge, exclusivity, chemistry, prescribing and regulatory information for more than 10,000 molecules, 18,000 companies, 68 markets and 92 patent countries worldwide with unique, early API development and manufacturing intelligence. They build on the substantial success of Horizon Global, by adding patented and published routes of synthesis on thousands of molecules, with listed intermediates and reagents, sourced from Prous Science's respected Synthline database. Newport Horizon Premium also has kilogram and IU (International Units) API consumption data from IMS Health added to the data and capabilities already available. This data is now available for thousands of drugs by region and by dose form for both the current and previous year and allow customers to evaluate scale, consumption trends and prices for active ingredients, all of which can be difficult to estimate using sales data alone.

NHP addresses the needs of large and small players in the pharmaceuticals market and features powerful multi-criteria search functionalities. It is aimed at helping generic, OTC and API companies in their constant struggle to build deals faster and accelerate time to market.

IDRAC is a single authoritative source of global regulatory intelligence for drug development, registration and commercialisation in almost 60 countries and regions, replacing the time-consuming tasks of acquiring, compiling and analyzing this information. With IDRAC, pharmaceutical companies can plan clinical trials better, accelerate product registration and commercialization and optimise market penetration. NHP and IDRAC are available in Indonesia through Scientific's representative in Indonesia, PT Piranti.

The Scientific business of Thomson Reuters provides information and knowledge to accelerate research, discovery and innovation. Our authoritative, accurate and timely information is essential for drug companies to discover new drugs and get them to market faster; researchers to find relevant papers and know what's newly published in their subject; and businesses to optimize their intellectual property and find competitive intelligence. We create the research platforms and services of the future that will power our customers toward business and personal success. Scientific information solutions can be found at scientific.thomsonreuters.com.

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.

Contact:

Pamela Lim

Manager, PR & Communications

Scientific

Tel: +65-6411-6737

Email: Pamela.lim@thomsonreuters.com


'/>"/>
SOURCE Thomson Reuters
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s Insight Behavioral Health ... anxiety disorders, has rebranded its eating disorder program under a new name: Eating Recovery ... facility on May 16. , To celebrate, ERC Chicago will host a ribbon-cutting ...
(Date:5/2/2016)... , ... May 02, 2016 , ... ... Data Book for the 2016 Main Residency Match® (“the Match”), the system through ... United States teaching institutions. A record-high 30,750 positions were placed in the 2016 ...
(Date:5/2/2016)... ... May 02, 2016 , ... East Los Angeles dentist , ... can visit Dr. Assili to receive any dental extraction treatment for $40 off the ... June 30, 2016. With the lower price, patients can more easily afford extractions to ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... new Specialty Pharmacy Patient Satisfaction Award that will recognize specialty pharmacies for their ... from Zitter Health Insights’ Specialty Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results ...
(Date:5/2/2016)... PORT RICHEY, Fla. (PRWEB) , ... ... ... experts and medical researchers report that many commonly used prescription medications, including ... loss (1). To mitigate these risks, Novus Medical Detox Center —a ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... BERLIN , April 29, 2016 ... world-leading glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years ... pharmaceutical and biotechnology industries. His last role was at ... Member of the Executive Board. Previously Dr. Zurlo held ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... April 28, 2016 ... George Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter ... heute bekannt, dass neue Führungskräfte zum Team ... sind, die vielfältige Erfahrungen mitbringen.  Dies wird ...
Breaking Medicine Technology: